Microbial production of phase I and phase II metabolites of midazolam

References

• Bjornsson TD. et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443–469.
   PubMed Web of Science ®Google Scholar
• Christensen H, Mathiesen L, Postvoll LW, Winther B, Molden E. (2009). Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources. Drug Metab Pharmacokinet 24:261–268.
   PubMed Web of Science ®Google Scholar
• Dundee JW, Halliday NJ, Harper KW, Brogden RN. (1984). Midazolam. A review of its pharmacological properties and therapeutic use. Drugs 28:519–543.
   PubMed Web of Science ®Google Scholar
• Emoto C, Iwasaki K. (2007). Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1′-hydroxylation. Xenobiotica 37:592–603.
   PubMed Web of Science ®Google Scholar
• Emoto C, Murase S, Sawada Y, Iwasaki K. (2005). In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet 20:351–357.
   PubMedGoogle Scholar
• Engstrom KM, Daanen JF, Wagaw S, Stewart AO. (2006). Gram scale synthesis of the glucuronide metabolite of ABT-724. J Org Chem 71:8378–8383.
   PubMed Web of Science ®Google Scholar
• Fischer B, Nudelman A, Ruse M, Herzig J, Gottlieb HE, Keinan E. (1984). A Novel Method for Stereoselective Glucuronidation. J Org Chem 49:4988–4993.
   Web of Science ®Google Scholar
• Grogan GJ, Holland HL. (2000). The biocatalytic reactions of Beauveria spp. J Mol Cat B Enzym 9:1–32.
   Google Scholar
• Heizmann P, Eckert M, Ziegler WH. (1983). Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16 Suppl 1:43S–49S.
   Google Scholar
• Heizmann P, Ziegler WH. (1981). Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31:2220–2223.
   PubMed Web of Science ®Google Scholar
• Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B. (2009). In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 67:445–454.
   PubMed Web of Science ®Google Scholar
• Jian Z, Wu A, Lin M, Lawrence J, Ray T. (2010). Synthetic studies of [M+5] hydroxymidazolam. J Label Compd Radiopharm. Special issues: 10th international symposium on the synthesis and applications of isotopes and isotopically labelled compounds—synthesis of compounds labelled with long-lived isotopes, June 2009, 53:239–268.
   Web of Science ®Google Scholar
• Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G. (2008). Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 36:851–862.
   PubMed Web of Science ®Google Scholar
• Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J. (2009). Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica 39:140–147.
   PubMed Web of Science ®Google Scholar
• Marvalin C, Azerad R. (2011a). Microbial glucuronidation of polyphenols. J Mol Catal B: Enzym. (In Press). Doi:10.1016/j.molcatb.2011.07.015.
   PubMedGoogle Scholar
• Marvalin C, Azerad R. (2011b). Microbial production of phase I and phase II metabolites of propranolol. Xenobiotica 41:175–186.
   PubMed Web of Science ®Google Scholar
• Muchohi SN, Ward SA, Preston L, Newton CR, Edwards G, Kokwaro GO. (2005). Determination of midazolam and its major metabolite 1′-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. J Chromatogr B Analyt Technol Biomed Life Sci 821:1–7.
   PubMed Web of Science ®Google Scholar
• Nicoli R, Bartolini M, Rudaz S, Andrisano V, Veuthey JL. (2008). Development of immobilized enzyme reactors based on human recombinant cytochrome P450 enzymes for phase I drug metabolism studies. J Chromatogr A 1206:2–10.
   PubMed Web of Science ®Google Scholar
• Rogers JF, Rocci ML Jr, Haughey DB, Bertino JSJr.(2003). An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 73:153–158.
   PubMed Web of Science ®Google Scholar
• Roy SN, Denoux M, Brasseur D, Philippe N, De Bruin B, Perard S, Allen J. (2007). The use of biocatalysis in the synthesis of labelled compounds. J Label Compd Radiopharm 50:342–346.
   Web of Science ®Google Scholar
• Scheinmann F, Lumbard KW, Brown RT, Mayalarp SP, Carter NE. (1993). A process for making morphine-6-glucuronide or substituted morphine-6-glucuronide. 18.02.1993, WO 93/03051.
   Google Scholar
• Seo KA, Bae SK, Choi YK, Choi CS, Liu KH, Shin JG. (2010). Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos 38:2007–2013.
   PubMed Web of Science ®Google Scholar
• Siddle DW, Faithfull L, Gleave M, Wright P, Lindsay N, Kohl C. (2003). Midazolam is metabolised by UGT1A4 in human hepatocytes and hepatic microsomes. Drug Metabol Rev, 35 (Suppl 1):55.
   Google Scholar
• Streetman DS, Bertino JS Jr, Nafziger AN. (2000). Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187–216.
   PubMedGoogle Scholar
• Walser A, Benjamin LE, Flynn T, Mason C, Schwartz R, Fryer RI. (1978). Quinazolines and 1,4-benzodiazepien. 84. Synthesis and reactions of imidazo[1,5-a][1,4]benzodiazepines. J Org Chem 43:936–944.
   Web of Science ®Google Scholar
• Zhang Y, Griendling KK, Dikalova A, Owens GK, Taylor WR. (2005). Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2. Hypertension 46:732–737.
   Google Scholar
• Zhu B, Bush D, Doss GA, Vincent S, Franklin RB, Xu S. (2008). Characterization of 1′-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos 36:331–338.
   PubMed Web of Science ®Google Scholar